I have copied this from 'Veeone' who posted it on SScene, hope...

I have copied this from 'Veeone' who posted it on SScene, hope they don,t mind.

From the Agm chairmans address
I have long held the view that Chairmen, Directors and Senior Management should focus on running the business, getting the job done and maximising performance, and let the share price respond accordingly, that is, “the market is the market.”
However, I intend to break that rule of mine today.
My colleagues and I are intensely frustrated by our current share price and the consequent
market value being ascribed to our company. This is particularly so when you consider the
current market value for Ventracor with what we have now achieved with 160 VentrAssist
implants, and also if you compare the current value with Ventracor’s historical market value when we were at a much earlier stages.
We have progressed to the very strong competitive position we have now reached without this being reflected in the overall value of Ventracor. As I said, it is very frustrating!
We continue to actively engage key institutional investors in Australia, US and Europe and we are working with investment analysts worldwide, particularly those in the US who follow the LVAD space, to tell the “Ventracor Story.”
In the last year, many more investment analysts who report on our key competitor Thoratec, have reported that Ventracor is the one company who is gaining the most ground, and is closest to gaining US market approval with an advanced technology device, the VentrAssist.
How do they think the shareholders feel then!!!